http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-509966-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_634d7355c2673489b2f4f800541770bb |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-003 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-206 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 |
| filingDate | 1999-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2dce7e9c9d96360dada651dc5aa64ab0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8af1a7bbd118598dde7582f8904fabe9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a30269e4fa30237c47b59c66969e6c8 |
| publicationDate | 2003-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-509966-A |
| titleOfInvention | Recombinant vector comprising a cassette with TET-ON under the control of a heat shock promoter, a cassette with a cloning site for a therapeutic gene, a cassette comprising antisense TET-ON and cassette with a dominative negative TET-ON and its use for metastatic prostate, breast and ovarian cancer |
| abstract | A recombinant vector pDATH-X (Dominant negative, Antisense, TET-ON controllable Heat shock promoter plasmid) comprises 4 cassettes. Cassette 1 comprises TET-ON expressed under the control of a heat shock promoter and a tet operator. The TET-ON consists of a fusion of the coding sequence for amino acids 1-207 of tetracycline repressor and the C-terminus last 130 amino acid transcription activation domain of VP1 protein of the herpes simplex virus. The heat shock promote consists of heat shock response elements (-260 to 30) of the human heat shock 70 gene promoter linked to a minimal cytomegalovirus promoter (pCMV) and the tet operator consists of 19bp inverted repeats of O2 of TN10 to which the tet repressor and TET-ON bind. Cassette 2 comprises a cloning site for a therapeutic gene downstream of a tetp-CMV promoter consisting of a tet operator linked to a minimal cytomegalovirus promoter (pCMV). The tet operator consists of 19bp inverted repeats of operator of TN10 to which the tet repressor and TET-ON bind. Cassette 3 comprises antisense TET-ON under the control of a pCMV promoter. The TET-ON is an antisense sequence complementary to the first 80 nucleotides of the TET-ON sequence. Cassette 4 comprises a dominant negative TET-ON under the control of pCMV promoter. The dominant negative TET-ON consists of tet repressor without a VP16 transactivation domain. The vector can be used in achieve localized, temporal expression of a gene that has been inserted into the vector so is under the control of a heat inducible promoter. The vector is inserted into the non-human host organism and the heat energy applier to a location of the organism where the expression of the gene is desired. Also described is a recombinant pDATE-X vector (Dominant negative, Antisense, TET-ON controllable EGR promoter expression plasmid), recombinant pRIBs-X (Radiation-Inducible Breast-specific Promoter) expression vector, recombinant pRIPs-X (Radiation-Inducible Prostate-specific Promoter) expression vector, recombinant pHIBs-X (Heat-Inducible Breast-specific Promoter) expression vector and a recombinant pHIBs-X (Heat Inducible Prostate-specific Promoter) expression vector. These vectors can be used for treating local and metastatic breast, ovarian and prostate cancer. Preferably the therapeutic gene is tumor necrosis alpha. |
| priorityDate | 1998-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.